Xilio Therapeutics Inc (XLO): Rasio rega marang pendapatan

Tandha merek xiliotx.com (XLO)

Xilio Therapeutics, Inc. (XLO) possesses high profit potential based on the scalable synthesis of targeted oncology drugs. The price-to-sales valuation on GURU.Markets reflects the asset's dynamics, where the parameter value reaches 1.00. Financial stability is ensured by the prudent allocation of the R&D budget, while the development strategy relies on organic growth and synergies from partner licensing agreements.

Xilio Therapeutics, Inc. (XLO): Rasio rega marang pendapatan saka 10.08.2024 nganti 16.11.2026

Xilio Therapeutics, Inc. (XLO) - rincian metrik lan laporan keuangan

- data kapitalisasi bursa:
Analisis umum perusahaan:Xilio, XLO
Produk dadi Xilio

The P/S ratio reflects the relationship between the market capitalization of Xilio Therapeutics, Inc. (XLO) and its total revenue, measuring the premium the market is willing to pay per unit of sales. This metric determines the asset's investment attractiveness through a balance of capital protection and potential growth. For Xilio Therapeutics, Inc. (XLO), this indicator is speculative in nature, as the absence of commercial products shifts the valuation toward future FDA approvals. By analyzing the divergence of the P/S ratio from its historical average on GURU.Markets, an investor assesses current market expectations regarding the company's future pricing power.

Perusahaan pesaing

ONC - Rega marang dodolan|Multiplikator P/S HALO (Halozyme Therapeutics, Inc.)|Revolution Medicines (RVMD) - Rega marang dodolan|ascentage.com - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan CGON (cgoncology.com)|URGN: Multiplikator P/S|Bicara Therapeutics Inc (BCAX) - Multiplikator P/S|Rasio rega marang pendapatan personalis.com|Kapitalisasi marang pendapatan Erasca Corp (ERAS)|Kapitalisasi marang pendapatan DCTH (Delcath)|Koefisien rega marang pendapatan Y-mAbs Therapeutics, Inc.|Multiplikator P/S AURA (Aura Biosciences Inc)|Rasio kapitalisasi pasar marang pendapatan CADL|ARAY: Kapitalisasi marang pendapatan|Koefisien rega marang pendapatan sellaslifesciences.com SLS|ACTU (Actuate Therapeutics, Inc) - Kapitalisasi marang pendapatan|Rasio kapitalisasi marang pendapatan CTOR|Rasio rega marang pendapatan TuHURA Biosciences Inc.|TARA: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Fate Therapeutics (FATE)|Koefisien rega marang pendapatan Aadi Bioscience|Rasio rega marang pendapatan TScan Therapeutics Inc TCRX|CSBR: Rasio kapitalisasi marang pendapatan|XBIT: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan CVM (cel-sci.com)|OSTX: Multiplikator P/S|Rega marang dodolan Radiopharm Theranostics Ltd (RADX)|ARTV (Artiva) - Multiplikator P/S|Rasio kapitalisasi marang pendapatan ANL (Adlai Nortye)|Rasio rega marang pendapatan Veru Pharma (VERU)|Multiplikator P/S Tempest Tx (TPST)|Multiplikator P/S RENB (Enochian BioSciences)|Mural Bio - Rasio rega marang pendapatan|KAPA - Rasio rega marang pendapatan|OnKure Therapeutics (OKUR) - Kapitalisasi marang pendapatan|GDTC: Multiplikator P/S|Rega marang dodolan Curis Corp (CRIS)|APLM (apollomicsinc.com) - Multiplikator P/S|Kapitalisasi marang pendapatan Tharimmune Corp (THAR)|Multiplikator P/S ADVB|GNPX - Rega marang dodolan|Rasio rega marang pendapatan calidibio.com CLDI|SBFM - Kapitalisasi marang pendapatan|XBIO - Rasio rega marang pendapatan|SLRX: Rasio rega marang pendapatan|Purple Biotech (PPBT) - Rasio rega marang pendapatan|AON - Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan BGNE|Multiplikator P/S Checkpoint Therapeutics Inc.|Multiplikator P/S ELEV|Kapitalisasi marang pendapatan iCAD ICAD|Multiplikator P/S IKNA (Ikena Oncology, Inc.)|Rasio kapitalisasi pasar marang pendapatan NTBL|Viracta Therapeutics, Inc. - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan MOR (MorphoSys Inc)|NAYA (NAYA Biosciences Inc) - Kapitalisasi marang pendapatan|Kapitalisasi marang pendapatan Ascentage Pharma Group Ltd